from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A human monoclonal antibody designed for the treatment of cancer of the head and neck.


Sorry, no etymologies found.


  • Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

    European Stocks Finish Flat

  • Genmab A/S has announced it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combinatio ...


  • In March, we announced top-line results from a zalutumumab Phase III study in refractory head and neck chemotherapy.


  • Patients in the study will be randomized into two treatment groups: zalutumumab in combination with best supportive care or best supportive care alone.


  • COPENHAGEN, Denmark, Jan. 5, 2009 (GLOBE NEWSWIRE) -- Genmab A / S (OMX: GEN) announced today that the interim survival analysis of the Phase III pivotal study investigating zalutumumab


  • The objective of the study is to evaluate the efficacy of zalutumumab incombination with best supportive care as compared to best supportive care alone in terms of overall survival.


  • Patients treated with zalutumumab in combination with best supportive care will receive an initial dose of 8mg / kg of zalutumumab, followed by weekly infusions of a maintenance dose until disease progression.


  • An Independent Data Monitoring Committee (IDMC) has evaluated the interimresults and concluded that the benefit-risk profile of zalutumumab isacceptable.


  • The maintenance dose will be adjusted as necessary until the patient develops a dose limiting skin rash, up to a maximum dose of 16 mg / kg of zalutumumab.


  • For zalutumumab: The FDA placed a partial clinical hold on zalutumumab clinical studies being conducted under the US Investigational New Drug (IND) application, as well as requests for new studies in June 2009. / TICKER


Log in or sign up to get involved in the conversation. It's quick and easy.